Crohn'
Conditions
Interventions
1.To collect approximately 20ml of peripheral blood from CD patients who are under medical examination and treatment in Hyogo College of Medicine. 2.To be provided approximately 30g of intestinal s
Sponsors
Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine
Sanwa Kagaku Kenkyusho Co,, Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who had a diagnosis of CD before participation to this study and who was able to provide written informed consent to be collected approximately 20ml of peripheral blood. 2.The CD patients who had necessity for intestinal resection because of exacerbation and who was able to provide written informed consent to provide approximately 30g of resected tissue in their surgery.
Exclusion criteria
Exclusion criteria: 1.Patients who could not provide written informed consent to be provide peripheral blood or intestinal tissue. 2.Patient who was administrated high dose of corticosteroids.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To confirm whether propagermanium inhibit the secretion of the inflammatory cytokines from LPS-stimulated human PBMC and LPMC. | — |
Secondary
| Measure | Time frame |
|---|---|
| To explore the clinical and the therapeutic background of responders to propagermanium. | — |
Countries
Japan
Contacts
Public ContactKazuko Nagase
Hyogo College of Medicine Department of Inflammatory Bowel Disease, Division of Internal Medicine
Outcome results
None listed